Background: A phase I trial of induction cisplatin, docetaxel, 5-FU and erlotinib (TPF-E) followed by cisplatin, bevacizumab and erlotinib (PA-E) with radiotherapy (XRT) for advanced head and neck cancer (HNC) was conducted.
American Society for Therapeutic Radiation Oncology (ASTRO) 52nd Annual Meeting October 31 - November 4, San Diego, CA
Ahn, P. H.; Machtay, M.; Anné, P. R.; Wuthrick, E.; Keane, W. M.; Cognetti, D.; Dicker, A. P.; and Axelrod, R. S.
"Results of a Phase I Trial of Induction Cisplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib with Radiotherapy for Advanced Head and Neck Cancer,"
1, Article 22.
Available at: http://jdc.jefferson.edu/bodinejournal/vol3/iss1/22